AU · rank #1 · 2026-07-20
TOI
NASDAQ · $535M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 3.208 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.06 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $235,110 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $8.40 | +57.0% |
| Momentum acceleration 3-month minus 12-month momentum. | +44.60% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 5.00 |
| Gross margin TTM | +15.1% |
| 52w high | $6.67 |
| Market cap (USD) | $535M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
TOI is a leading value-based community oncology group in the United States, driving capitated revenue through risk-based contracts and a rapidly expanding specialty pharmacy segment.
Rationale
The positive revision signals are backed by a strong Q1 2026 earnings beat, an upward revision in free cash flow guidance to $5–$15 million, and a strategic July 2026 refinancing with OrbiMed that extended debt maturities without equity dilution [RECENT_DEVELOPMENTS, FINANCIAL_NOTES].
Material risks
- 1Highly concentrated exposure to regulatory changes and reimbursement rate resets within Medicare Advantage and CMS value-based programs could severely compress capitated revenue margins [BUSINESS_STATUS, TOP_RISKS].
- 2The company remains GAAP loss-making, and its newly structured $75 million term loan maintains a heavy debt burden that requires flawless operational execution to service [FINANCIAL_NOTES, TOP_RISKS].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.